Nasdaq:ABCL
AbCellera Biologics Inc.
AbCellera Biologics is a biotech firm developing CAR-T cell therapies for oncology and autoimmune diseases with a strategic partnership driving its revenue model.
Key Metrics
Investment Thesis
Bull Case
Investors might buy ABCL due to its proprietary cell therapy platform which offers high potential value upon successful regulatory approval and commercialization of oncology treatments. The strategic partnership with Eli Lilly provides a stable revenue base and shared risk that could lead to significant upside if clinical trials succeed. The company's strong balance sheet with $153.5M in ending cash and $61.8M in cash equivalents offers a buffer to continue R&D spending without immediate dilution.
Bear Case
Investors should avoid ABCL due to the severe revenue contraction over the past three years, dropping from $485.4M in 2022 to $75.1M in 2025, which signals potential instability in its business model. Persistent negative net income and cash flow from operations indicate that the company is not yet generating sustainable commercial returns from its pipeline. The heavy reliance on a single major partner and ongoing high operating expenses ($292.2M) create uncertainty about future profitability and cash runway.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) is a biotechnology company advancing cell therapy solutions primarily through its collaboration with Eli Lilly to develop CAR-T cell therapies for oncology and autoimmune diseases. The company leverages proprietary platforms like the ABCELLERA platform to generate revenue while investing heavily in R&D and capital expenditures. Operating mainly in the North American market, AbCellera focuses on translating early-stage research into commercialized cell therapies.
Analysis
Management Discussion
Management has navigated a challenging period marked by a dramatic decline in reported revenue from 2022 to 2024 before a partial recovery in 2025, reflecting the complex transition phases often seen in collaborative biotech ventures. Despite significant operating losses of $-217.1M and cash flow from operations of $-131.3M, the company maintained a strong equity position with $966.9M in shareholders' equity and utilized financing activities to raise $14.1M. The substantial investment in research and development ($186.8M) underscores a strategic commitment to pipeline growth despite current profitability constraints.
Industry Overview
The biotechnology industry, particularly in cell therapy and oncology, is characterized by high capital requirements, long development cycles, and significant regulatory hurdles before products reach market. Companies like AbCellera operate in a competitive landscape where proprietary technology and strategic partnerships are crucial for survival and growth. Recent trends show a shift towards collaboration between biotech firms and large pharmaceutical companies to share the financial burden of expensive clinical trials.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $485.4M | $38.0M | $28.8M | $75.1M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $485.4M | $38.0M | $28.8M | $75.1M |
| Operating Expenses | $268.9M | $275.2M | $343.6M | $292.2M |
| Operating Income | $216.5M | $-237.2M | $-314.8M | $-217.1M |
| R&D | $107.9M | $175.7M | $167.3M | $186.8M |
| G&A | $55.5M | $61.0M | $72.7M | $83.2M |
| Marketing | $11.3M | $14.2M | $12.8M | — |
| Stock-Based Comp | $49.5M | $64.2M | $67.6M | $55.8M |
| D&A | — | $24.4M | — | — |
| Depreciation | $9.0M | $12.8M | $12.5M | $18.4M |
| Amortization | $10.5M | $11.6M | $14.3M | $3.7M |
| Other OpEx | $94.3M | $24.4M | $90.8M | $22.2M |
| Non-Operating Income | $22.6M | $63.2M | $114.4M | $39.5M |
| Interest Income | $16.1M | $42.2M | $38.5M | $28.3M |
| Pre-Tax Income | $239.1M | $-174.0M | $-200.4M | $-177.6M |
| Income Tax | $80.6M | $-27.6M | $-37.5M | $-31.2M |
| Continuing Ops | $158.5M | $-146.4M | $-162.9M | $-146.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $158.5M | $-146.4M | $-162.9M | $-146.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $158.5M | $-146.4M | $-162.9M | $-146.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.03B | $872.0M | $751.4M | $728.2M |
| Cash & Equivalents | $44.9M | $52.2M | $55.6M | $61.8M |
| Inventory | — | — | — | $6.3M |
| Other Current Assets | $980.6M | $819.8M | $695.8M | $660.1M |
| Long-Term Assets | $515.4M | $616.1M | $609.2M | $628.7M |
| PP&E (Net) | $217.3M | — | — | — |
| Intangibles | $131.5M | $120.4M | $42.1M | $38.4M |
| Goodwill | $47.8M | $47.8M | $47.8M | $47.8M |
| Operating Leases | — | $73.1M | $66.6M | $136.1M |
| Other LT Assets | $118.9M | $374.7M | $452.6M | $406.4M |
| Total Assets | $1.54B | $1.49B | $1.36B | $1.36B |
| Current Liabilities | $118.3M | $119.0M | $76.6M | $64.3M |
| Current Leases | $5.6M | $6.2M | $4.6M | $5.8M |
| Deferred Revenue | $21.6M | $19.0M | $13.5M | $13.5M |
| Other Current Liab | $91.1M | $93.9M | $58.5M | $45.0M |
| Long-Term Liabilities | $189.3M | $216.8M | $227.9M | $325.7M |
| LT Operating Leases | $76.7M | $71.2M | $60.7M | $137.4M |
| Other LT Liab | $93.1M | $137.3M | $161.4M | $188.3M |
| Total Liabilities | $307.6M | $335.8M | $304.5M | $390.0M |
| Shareholders' Equity | $1.23B | $1.15B | $1.06B | $966.9M |
| Retained Earnings | $426.2M | $279.8M | $116.9M | $-29.5M |
| AOCI | $-1.4M | $-1.7M | $-4.4M | $-4.2M |
| Total L&E | $1.54B | $1.49B | $1.36B | $1.36B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $158.5M | $-146.4M | $-162.9M | $-146.4M |
| Non-Cash Adjustments | $186.5M | $49.1M | $-24.2M | $5.2M |
| Working Capital Changes | $-67.6M | $53.4M | $78.5M | $9.9M |
| Cash from Operations | $277.4M | $-43.9M | $-108.6M | $-131.3M |
| Capital Expenditures | $70.7M | $76.9M | $78.4M | $42.8M |
| Cash from Investing | $-352.6M | $-221.1M | $121.4M | $87.8M |
| Cash from Financing | $-1.6M | $10.4M | $12.8M | $14.1M |
| FX Effect | $-9.6M | $589.0K | $-2.6M | $1.1M |
| Net Change in Cash | $-86.5M | $-254.0M | $23.0M | $-28.4M |
| Beginning Cash | $501.1M | $411.5M | $158.3M | $181.3M |
| Ending Cash | $411.5M | $158.3M | $181.3M | $153.5M |
Frequently Asked Questions
How does AbCellera Biologics Inc. make money?
The company's financials indicate a single primary business segment focused on cell therapy development and licensing, evidenced by significant research and development expenditures ($186.8M) relative to total revenue ($75.1M). Revenue streams are heavily dependent on collaboration agreements, such as the partnership with Eli Lilly, which accounts for the majority of reported gross profit. The balance sheet shows substantial other shareholders equity ($1.0B) and long-term assets, suggesting a capital-intensive structure typical of biotech firms focused on pipeline advancement rather than diversified product lines.
What are the main risks for ABCL?
The company faces significant commercial risk as revenue dropped sharply from $485.4M in 2022 to $75.1M in 2025, indicating potential volatility in partnership payments or transition periods. Sustained negative net income over the last three years ($-146.4M in 2023, -162.9M in 2024) highlights a reliance on future product approvals and commercial success to achieve profitability. High capital expenditures ($42.8M) and operating expenses ($292.2M) create pressure on cash reserves, with ending cash at $153.5M needing careful management against ongoing burn rates. Regulatory approval risks for their cell therapy products remain a critical factor that could impact future revenue realization.
What is ABCL's competitive advantage?
AbCellera possesses a proprietary platform technology that accelerates the development of CAR-T cells, reducing time-to-market compared to traditional methods. The company benefits from a strategic partnership with a major pharmaceutical giant like Eli Lilly, providing financial stability and shared clinical trial resources. Its focus on both oncology and autoimmune indications expands its potential addressable market beyond just cancer treatments.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.